CA2060139C - Triazole derivative - Google Patents
Triazole derivativeInfo
- Publication number
- CA2060139C CA2060139C CA002060139A CA2060139A CA2060139C CA 2060139 C CA2060139 C CA 2060139C CA 002060139 A CA002060139 A CA 002060139A CA 2060139 A CA2060139 A CA 2060139A CA 2060139 C CA2060139 C CA 2060139C
- Authority
- CA
- Canada
- Prior art keywords
- indol
- triazol
- ethylamine
- dimethyl
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003852 triazoles Chemical class 0.000 title abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 15
- 206010027599 migraine Diseases 0.000 claims abstract description 15
- ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 claims abstract 20
- 239000000203 mixture Substances 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 7
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000018 receptor agonist Substances 0.000 claims description 6
- 229940044601 receptor agonist Drugs 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- 230000002460 anti-migrenic effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims 4
- 239000000556 agonist Substances 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical group C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- RLXDCJUIXHSXQD-UHFFFAOYSA-N oxalic acid;hydrate Chemical compound O.OC(=O)C(O)=O.OC(=O)C(O)=O RLXDCJUIXHSXQD-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZGLQVRIVLWGDNA-UHFFFAOYSA-N 4-(1,2,4-triazol-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1N=CN=C1 ZGLQVRIVLWGDNA-UHFFFAOYSA-N 0.000 description 1
- QXIUMMLTJVHILT-UHFFFAOYSA-N 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1C=C(C#N)N2 QXIUMMLTJVHILT-UHFFFAOYSA-N 0.000 description 1
- LTLKJYMNUSSFAH-UHFFFAOYSA-N 4-chloro-1,1-dimethoxybutane Chemical compound COC(OC)CCCCl LTLKJYMNUSSFAH-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- -1 amine hydrochloride Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229950008693 mesulergine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 208000007777 paroxysmal Hemicrania Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- MDUSUFIKBUMDTJ-UHFFFAOYSA-N sodium;1h-1,2,4-triazole Chemical compound [Na].C=1N=CNN=1 MDUSUFIKBUMDTJ-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Triazole derivative, namely N,N-dimethyl-2-[5-(1,2,4-triazol-1-yl-methyl)-1H-indol-3-yl]ethylamine and its pharmaceutically acceptable salts are selective agonists of 5-HT1-like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated. The triazole derivative is of formula:
Description
-The present invention relates to a triazole derivative which acts on 5-hydroxytryptamine (5-HT) receptors, being a selective agonist of so-called "5-HTl-like" receptors. It is therefore useful in the treatment of clinical conditions for which a selective agonist of these receptors is indicated.
5-HTl-like receptor agonists which exhibit selective vasoconstrictor activity have recently been described as being of use in the treatment of migraine (see, for example, A. Doenicke et al., The Lancet, 1988, Vol. 1, 1309-11). The compound of the present invention, being a selective 5-HTl-like receptor agonist, is accordingly of particular use in the treatment of migraine and associated conditions, e.g. cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, tension headache and paediatric migraine.
EP-A-0313397 describes a class of tryptamine derivatives substituted by a five-membered heteroaliphatic ring, which are stated to be specific to a particular type of "5-HTl-like" receptor and thus to be effective therapeutic agents for the treatment of clinical conditions, particularly migraine, requiring this activity. However, EP-A-0313397 neither discloses nor suggests the triazole derivatives provided by the present invention.
The invention relates to the triazole derivative N,N-dimethyl-2-[5-(1,2,4-triazol-1-yl-methyl)-lH-indol-3-yl~ethylamine of formula:
~ ~-CH2- ~ ~ CH2C~I2N(CH3)2 or a salt thereof.
In another aspect the invention relates to a pharmaceutical composition comprising the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or excipient. More especially, the invention in this aspect relates to an anti-migraine phrmaceutical composition comprising an acceptable, anti-migraine effective amount of the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
In yet another aspect of the invention there is provided use of the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof, in or for the manufacture of a medicament for the treatment of migraine and associated conditions.
In still another aspect of the invention there is provided the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine or associated conditions.
In yet another aspect of the invention there is provided use of the triazole of the invention, or a pharmaceutically acceptable salt thereof, as a 5-HTl-like receptor agonist.
For use in medicine, the salts of the triazole derivative of formula I will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the triazole derivative according to the invention or of its non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the triazole derivative of this invention include acid addition salts which may, for example, be formed by mixing a solution of the derivative according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
The invention also provides pharmaceutical compositions comprising the triazole derivative or one or more salts thereof in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the triazole derivative of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogenous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetatè.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such a tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
In the treatment of migraine, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The triazole derivative or salts thereof may be administered on a regimen of 1 to 4 times per day.
The following Examples illustrate the preparation of compounds according to the invention.
The ability of test compounds to bind to S-HT1-like receptors was measured in membranes prepared from pig caudate using the procedure described in J. Neurosci., 1987, 7, 894. Binding was determined using 2 nM 5-hydroxytryptamine creatinine sulphate, 5-[1,2-3H(N)] as a radioligand. Cyanopindolol (lOO nM) and mesulergine (100 nM) were included in the assay to block out 5-HT1A and 5-HT1c binding sites respectively.
The concentration of the compounds of the accompanying Examples required to displace 50% of the specific binding (ICso) is below 1 ~M in each case.
The activity of test compounds as agonists of the 5-HT1-like receptor was measured in terms of their ability to mediate contraction of the saphenous vein of New Zealand White rabbits, using the procedure described in Arch. Pharm., 1990, 342, 111. Agonist potencies were calculated as -logloECso (pECso) values, from plots of percentage 5-HT (1 ~m) response against the concentration of the agonist. The compounds of the accompanying Examples were found to possess pECso values in this assay of not less than 5.0 in each case.
EXAMPLE I
N,N-DimethY1-2[5-(1,2,4-triazol-1-Y1-methY1)-lH-indol-3-yl]ethYlamine. Oxalate HemihYdrate 1. 1-(4-NitrophenYl)methY1-1,2,4-triazole 4-Nitrobenzylbromide (21.6g, 0.1mol) was added to a rapidly stirred suspension of 1,2,4-triazole sodium salt (9.lg, 0.1mol) in anhydrous DMF (100 ml) and the mixture stirred at room temperature for 16h. Ethyl acetate (400ml) was added followed by water (250ml) and the layers separated. The organic phase was washed with water (3 x 25Oml), dried (MgSO4) and evaporated. The residue was chromatographed on silica gel eluting with ethyl acetate to give the title-Product (10.6g, 52%);
m.p. 98-100~C. ~ (360MHz, CDCL3) 5.47 (2H, s, CH2) 7.40 (2H, d, J = 9Hz, Ar-H), 8.02 (lH, s, Ar-H), 8.18 (lH, s, Ar-H), 8.23 (2H, d, J = 9Hz, Ar-H).
2. 1-(4-Aminophenyl)methyl-1,2,4-triazole. Hydrochloride A solution of 1-(4-nitrophenyl)methyl-1,2,4-triazoIe (10.0g, 49mmol) in ethanol (50ml), ethyl acetate (50ml), 5N HCl (10ml) and water (10ml) was hydrogenated over 10 Pd/C (1.0g) at 40 p.s.i., in a Parr apparatus, until an uptake of 188 p.s.i., had been observed (approx. 10 mins.). The catalyst was removed by filtration through Hyflo and the solvent removed under vacuum. The residue was azeotroped with ethanol (x2) to give the title-amine hydrochloride (10.6g, 100%). ~ (360MHz, D2O) 5.53 (2H, s, CH2), 7.37-7.48 (3H, m, Ar-H), 8.12 (lH, s, Ar-H), 8.66 (lH, s, Ar-H). Hyflo is a Trade-mark.
5-HTl-like receptor agonists which exhibit selective vasoconstrictor activity have recently been described as being of use in the treatment of migraine (see, for example, A. Doenicke et al., The Lancet, 1988, Vol. 1, 1309-11). The compound of the present invention, being a selective 5-HTl-like receptor agonist, is accordingly of particular use in the treatment of migraine and associated conditions, e.g. cluster headache, chronic paroxysmal hemicrania, headache associated with vascular disorders, tension headache and paediatric migraine.
EP-A-0313397 describes a class of tryptamine derivatives substituted by a five-membered heteroaliphatic ring, which are stated to be specific to a particular type of "5-HTl-like" receptor and thus to be effective therapeutic agents for the treatment of clinical conditions, particularly migraine, requiring this activity. However, EP-A-0313397 neither discloses nor suggests the triazole derivatives provided by the present invention.
The invention relates to the triazole derivative N,N-dimethyl-2-[5-(1,2,4-triazol-1-yl-methyl)-lH-indol-3-yl~ethylamine of formula:
~ ~-CH2- ~ ~ CH2C~I2N(CH3)2 or a salt thereof.
In another aspect the invention relates to a pharmaceutical composition comprising the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or excipient. More especially, the invention in this aspect relates to an anti-migraine phrmaceutical composition comprising an acceptable, anti-migraine effective amount of the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
In yet another aspect of the invention there is provided use of the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof, in or for the manufacture of a medicament for the treatment of migraine and associated conditions.
In still another aspect of the invention there is provided the triazole derivative of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine or associated conditions.
In yet another aspect of the invention there is provided use of the triazole of the invention, or a pharmaceutically acceptable salt thereof, as a 5-HTl-like receptor agonist.
For use in medicine, the salts of the triazole derivative of formula I will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the triazole derivative according to the invention or of its non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the triazole derivative of this invention include acid addition salts which may, for example, be formed by mixing a solution of the derivative according to the invention with a solution of a pharmaceutically acceptable non-toxic acid such as hydrochloric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
The invention also provides pharmaceutical compositions comprising the triazole derivative or one or more salts thereof in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the triazole derivative of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogenous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetatè.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such a tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
In the treatment of migraine, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The triazole derivative or salts thereof may be administered on a regimen of 1 to 4 times per day.
The following Examples illustrate the preparation of compounds according to the invention.
The ability of test compounds to bind to S-HT1-like receptors was measured in membranes prepared from pig caudate using the procedure described in J. Neurosci., 1987, 7, 894. Binding was determined using 2 nM 5-hydroxytryptamine creatinine sulphate, 5-[1,2-3H(N)] as a radioligand. Cyanopindolol (lOO nM) and mesulergine (100 nM) were included in the assay to block out 5-HT1A and 5-HT1c binding sites respectively.
The concentration of the compounds of the accompanying Examples required to displace 50% of the specific binding (ICso) is below 1 ~M in each case.
The activity of test compounds as agonists of the 5-HT1-like receptor was measured in terms of their ability to mediate contraction of the saphenous vein of New Zealand White rabbits, using the procedure described in Arch. Pharm., 1990, 342, 111. Agonist potencies were calculated as -logloECso (pECso) values, from plots of percentage 5-HT (1 ~m) response against the concentration of the agonist. The compounds of the accompanying Examples were found to possess pECso values in this assay of not less than 5.0 in each case.
EXAMPLE I
N,N-DimethY1-2[5-(1,2,4-triazol-1-Y1-methY1)-lH-indol-3-yl]ethYlamine. Oxalate HemihYdrate 1. 1-(4-NitrophenYl)methY1-1,2,4-triazole 4-Nitrobenzylbromide (21.6g, 0.1mol) was added to a rapidly stirred suspension of 1,2,4-triazole sodium salt (9.lg, 0.1mol) in anhydrous DMF (100 ml) and the mixture stirred at room temperature for 16h. Ethyl acetate (400ml) was added followed by water (250ml) and the layers separated. The organic phase was washed with water (3 x 25Oml), dried (MgSO4) and evaporated. The residue was chromatographed on silica gel eluting with ethyl acetate to give the title-Product (10.6g, 52%);
m.p. 98-100~C. ~ (360MHz, CDCL3) 5.47 (2H, s, CH2) 7.40 (2H, d, J = 9Hz, Ar-H), 8.02 (lH, s, Ar-H), 8.18 (lH, s, Ar-H), 8.23 (2H, d, J = 9Hz, Ar-H).
2. 1-(4-Aminophenyl)methyl-1,2,4-triazole. Hydrochloride A solution of 1-(4-nitrophenyl)methyl-1,2,4-triazoIe (10.0g, 49mmol) in ethanol (50ml), ethyl acetate (50ml), 5N HCl (10ml) and water (10ml) was hydrogenated over 10 Pd/C (1.0g) at 40 p.s.i., in a Parr apparatus, until an uptake of 188 p.s.i., had been observed (approx. 10 mins.). The catalyst was removed by filtration through Hyflo and the solvent removed under vacuum. The residue was azeotroped with ethanol (x2) to give the title-amine hydrochloride (10.6g, 100%). ~ (360MHz, D2O) 5.53 (2H, s, CH2), 7.37-7.48 (3H, m, Ar-H), 8.12 (lH, s, Ar-H), 8.66 (lH, s, Ar-H). Hyflo is a Trade-mark.
3. 1-(4-Hydrazinophen~l)methyl-1,2,4-triazole A solution of sodium nitrite (3.28g, 48mmol) in water (20ml) was added to a solution of the preceding amine hydrochloride (10.Og, 48mmol), in concentrated HCl (40ml?, at such a rate that the temperature did not exceed -10~C. After addition was complete the solution was stirred at 0~C for 0.25h and then added portionwise to a rapidly stirred solution of SnC12.2H20 (40g) in concentrated HCl (40ml). The solution was 0 warmed to room temperature and basified with 20% aqueous NaOH solution. The solution was extracted with ethyl acetate (3 x 250ml) and the combined extracts dried (Mg~;04) and filtered through Hyflo. The solution was evaporated to dryness to give the desired hydrazine (5.0g, 56%) m.p. 109-112~C.
(360MHz, D6-DMSO) 3.93 (2H, br s, NH2), ~.20 (2H, s, CH2), 6.73 (2H, d, J = 8Hz, Ar-H), 7.08 (2H, d, J = 8Hz, Ar-H), 7.92 (lH, s, Ar-H), 8.57 (lH, s, Ar-H). E~yflo is a Trade mark.
(360MHz, D6-DMSO) 3.93 (2H, br s, NH2), ~.20 (2H, s, CH2), 6.73 (2H, d, J = 8Hz, Ar-H), 7.08 (2H, d, J = 8Hz, Ar-H), 7.92 (lH, s, Ar-H), 8.57 (lH, s, Ar-H). E~yflo is a Trade mark.
4. 2-[5-(1,2,4-Triazol-l-ylmeth~l)-lH-indol-3-yl]
ethyl~mine.
4-Chlorobutanal dimethylacetal (3.22g, 21.1mmol) was added to a stirred solution of the preceding hydrazine (~.0g, 26.4mmol) in ethanol/water (5:1, 180ml) and 5N HCl (4.5ml) and the, solution refluxed for 4h. The solvents were removed under vacuum and the residue chromatographed on silica gel, eluting with CH2C12/EtOH/NH3 (30:8:1) to give the desired tryptamine (2.4g, 38%). ~(360MHz, CDCl3) 2.90 (2H, t, J _ 7Hz, CH2), 2.99 (2H, t, J = 7Hz, CH2), 6.43 (2H, s, CH2), 7.10 (lH, s, Ar-H), 7.11 (lH, d, J = 8Hz, Ar-H), 7.39 (lH, d, J = 8Hz, Ar-H), 7.57 (lH, s, Ar-H), 7.94 (lH, s, Ar-H),8.08 (lH, s, Ar-H).
ethyl~mine.
4-Chlorobutanal dimethylacetal (3.22g, 21.1mmol) was added to a stirred solution of the preceding hydrazine (~.0g, 26.4mmol) in ethanol/water (5:1, 180ml) and 5N HCl (4.5ml) and the, solution refluxed for 4h. The solvents were removed under vacuum and the residue chromatographed on silica gel, eluting with CH2C12/EtOH/NH3 (30:8:1) to give the desired tryptamine (2.4g, 38%). ~(360MHz, CDCl3) 2.90 (2H, t, J _ 7Hz, CH2), 2.99 (2H, t, J = 7Hz, CH2), 6.43 (2H, s, CH2), 7.10 (lH, s, Ar-H), 7.11 (lH, d, J = 8Hz, Ar-H), 7.39 (lH, d, J = 8Hz, Ar-H), 7.57 (lH, s, Ar-H), 7.94 (lH, s, Ar-H),8.08 (lH, s, Ar-H).
5. N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-lH-indol-3-~,rl]ethylamine O~alateHemih:ydrate A solution of formaldehyde (37% w/w solution, O.l9g), in methanol (lOml), was added to a mixture of the preceding lo tryptamine (0.36g, 1.5mmol), NaCNBH3 (0.226g, 3.6mmol) and glacial acetic acid (0.46g), in methanol (lOml). The mi~ture was stirred at room temperature for 2h before adding saturated K2C03 (50ml) and evaporating the methanol. The residue was extracted with ethyl acetate (3 x lOOml) and the combined extracts washed with brine (lOOml), dried (K2C03), and evaporated. The crude product was chromatographed on silica gel eluting with CH2C12/EtOH/NH3 (20:8:1) to give the free base of the title-compound (0.21g, 52%). The oxalate hemihydrate salt was prepared, m.p. 166-167~C (MeOH/Et20);
(Found: C, 55.53; H, 6.04; N, 18.59. C15HlgN5.C2H204.
0.55H20 requires C, 55.29; H, 6.03; N, 18.96%); m/e 269 (M+); o (360MHz, D20) 2.91 (6H, s, NMe2), 3.22 (2H, t, J = 7Hz, CH2), 3.47 (2H, t, J = 7Hz, CH2), 5.52 (2H, s, CH2), 7.21 (lH, dd, J =
1.6 and 8.4Hz, Ar-H), 7.36 (lH, s, Ar-H), 7.52 (lH, d, J = 8.4Hz, Ar-H), 7.65 (lH, s, Ar-H), 8.06 (lH, s, Ar-H), 8.56 (lH, s, Ar-H).
. CA 02060139 1998-07-09 EXAMPLE ~
N,N-Dimeth srl-2-[5-( 1,2 ,4-triazol-lylmethyl)- lH-indol-3-yl]ethylamine. Succinate. Procedure B
A solution of 1-(4-hydrazinophenyl)methyi-1,2,4-triazole dihydrochloride (2g, 7.6mmol, Example l step 3) and 4-N,N-dimethylaminobutanal dimethylacetal (1.8g, 11.2mmol) in 4%
aqueous sulphuric acid (70ml) was heated at reflux for 2h. After the reaction mixture was cooled to room temperature, ethyl acetate (200ml) was added and the aqueous basified with K2CO3. The aqueous was separated and extracted further with ethyl acetate (2 x 150ml). The combined organics were dried (Na2SO4) and evaporated, and the residue chromatographed on silica gel eluting with CH2C12/EtOH/NH3 (30:8:1) to give the title-triazole (610mg, 30%). The succinate salt was prepared by addition of a solution of succinic acid (0.27g, 2.3mmol) in methanol (3ml) to a solution of the triazole (0.61g, 2.3mmol) in methanol (5ml). The solvent was removed under vacullm and the resultant product recrystallised from isopropylalcohol, mp 118-120~C; (Found: C, 58.76; H, 6.27; N, 17.79.
C16HlgN3.C4H604 requires C, 58.90; H, 6.60; N, 18.08%).
N,N-Dimethyl-2-[6-(1,2,4-triazol-1-ylmethyl)-lH-indol-3-~l]eth~lamine. Benzoate The benzoate salt of N,N-dimethyl-2-[5-(~ ,2,4-triazol-1-ylmethyl)-lH-indol-3-yl]ethylamine was prepared by addition of a solution of benzoic acid in diethyl ether to a solution of the free base in ethanoVdiethyl ether (1:4). The precipitated salt was recrystallised from ethanol, mp 178-180~C; (Found: C, 67.28; H, 6.65; N, 17.66. C15HlgN3.C6H5CO2H requires C, 67.50; H, 6.44; N, 17.89%); lH NMR (360MHz, D20) o 2.92 (6H, s, NMe2);
3.22 (2H, t, J = 7.3Hz, CH2); 3.46 (2H, t, J = 7.3Hz, CH2); 5.52 (2H, s, CH2); 7.22 (lH, dd, J = 1.6 and 8.4Hz, Ar-H); 7.36 (lH, s, Ar-H); 7.44-7.58 (4H, m, Ar-H); 7.65 (lH, s, Ar-H); 7.87-7.91 (2H, m, Ar-H); 8.06 (lH, s, Ar-H); 8.54 (lH, s, Ar-H).
Tablet Preparation Tablets cont~ining 1.0, 2.0, 25.0, 26.0, 50.0 and lOO.Omg, respectively of the following compound are prepared as illustrated below:
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-lH-indol-3-yl]ethyl Tnine. Benzoate.
TABLE FOR DOSES CONTAINING FROM
Amount-mg Active Compound 1.0 2.0 25.0 Microcrystalline cellulose 49.25 48.75 37.25 Modified food corn starch 49.25 48.75 37.25 Magnesium stearate 0.50 0.50 0.50 TABLE FOR DOSES CONTAINING FROM
26-lOOMG OF THE ACTIVE COMPOUND
Amount-mg Active ~ompound 26.0 50.0 100.0 Microcrystalline cellulose 52.0 100.0 200.0 Modified food corn starch 2.21 4.25 8.5 Magnesium stearate 0.39 0.75 1.5 All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste.
The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the m~gnesium stearate. The resulting granulation is then compressed into tablets conta;ning 1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active ingredient per tablet.
(Found: C, 55.53; H, 6.04; N, 18.59. C15HlgN5.C2H204.
0.55H20 requires C, 55.29; H, 6.03; N, 18.96%); m/e 269 (M+); o (360MHz, D20) 2.91 (6H, s, NMe2), 3.22 (2H, t, J = 7Hz, CH2), 3.47 (2H, t, J = 7Hz, CH2), 5.52 (2H, s, CH2), 7.21 (lH, dd, J =
1.6 and 8.4Hz, Ar-H), 7.36 (lH, s, Ar-H), 7.52 (lH, d, J = 8.4Hz, Ar-H), 7.65 (lH, s, Ar-H), 8.06 (lH, s, Ar-H), 8.56 (lH, s, Ar-H).
. CA 02060139 1998-07-09 EXAMPLE ~
N,N-Dimeth srl-2-[5-( 1,2 ,4-triazol-lylmethyl)- lH-indol-3-yl]ethylamine. Succinate. Procedure B
A solution of 1-(4-hydrazinophenyl)methyi-1,2,4-triazole dihydrochloride (2g, 7.6mmol, Example l step 3) and 4-N,N-dimethylaminobutanal dimethylacetal (1.8g, 11.2mmol) in 4%
aqueous sulphuric acid (70ml) was heated at reflux for 2h. After the reaction mixture was cooled to room temperature, ethyl acetate (200ml) was added and the aqueous basified with K2CO3. The aqueous was separated and extracted further with ethyl acetate (2 x 150ml). The combined organics were dried (Na2SO4) and evaporated, and the residue chromatographed on silica gel eluting with CH2C12/EtOH/NH3 (30:8:1) to give the title-triazole (610mg, 30%). The succinate salt was prepared by addition of a solution of succinic acid (0.27g, 2.3mmol) in methanol (3ml) to a solution of the triazole (0.61g, 2.3mmol) in methanol (5ml). The solvent was removed under vacullm and the resultant product recrystallised from isopropylalcohol, mp 118-120~C; (Found: C, 58.76; H, 6.27; N, 17.79.
C16HlgN3.C4H604 requires C, 58.90; H, 6.60; N, 18.08%).
N,N-Dimethyl-2-[6-(1,2,4-triazol-1-ylmethyl)-lH-indol-3-~l]eth~lamine. Benzoate The benzoate salt of N,N-dimethyl-2-[5-(~ ,2,4-triazol-1-ylmethyl)-lH-indol-3-yl]ethylamine was prepared by addition of a solution of benzoic acid in diethyl ether to a solution of the free base in ethanoVdiethyl ether (1:4). The precipitated salt was recrystallised from ethanol, mp 178-180~C; (Found: C, 67.28; H, 6.65; N, 17.66. C15HlgN3.C6H5CO2H requires C, 67.50; H, 6.44; N, 17.89%); lH NMR (360MHz, D20) o 2.92 (6H, s, NMe2);
3.22 (2H, t, J = 7.3Hz, CH2); 3.46 (2H, t, J = 7.3Hz, CH2); 5.52 (2H, s, CH2); 7.22 (lH, dd, J = 1.6 and 8.4Hz, Ar-H); 7.36 (lH, s, Ar-H); 7.44-7.58 (4H, m, Ar-H); 7.65 (lH, s, Ar-H); 7.87-7.91 (2H, m, Ar-H); 8.06 (lH, s, Ar-H); 8.54 (lH, s, Ar-H).
Tablet Preparation Tablets cont~ining 1.0, 2.0, 25.0, 26.0, 50.0 and lOO.Omg, respectively of the following compound are prepared as illustrated below:
N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-lH-indol-3-yl]ethyl Tnine. Benzoate.
TABLE FOR DOSES CONTAINING FROM
Amount-mg Active Compound 1.0 2.0 25.0 Microcrystalline cellulose 49.25 48.75 37.25 Modified food corn starch 49.25 48.75 37.25 Magnesium stearate 0.50 0.50 0.50 TABLE FOR DOSES CONTAINING FROM
26-lOOMG OF THE ACTIVE COMPOUND
Amount-mg Active ~ompound 26.0 50.0 100.0 Microcrystalline cellulose 52.0 100.0 200.0 Modified food corn starch 2.21 4.25 8.5 Magnesium stearate 0.39 0.75 1.5 All of the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste.
The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the m~gnesium stearate. The resulting granulation is then compressed into tablets conta;ning 1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active ingredient per tablet.
Claims (21)
1. N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, or a salt thereof.
2. N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine.
3. A pharmaceutically acceptable salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethylamine.
4. A salt according to claim 1, selected from the group consisting of the oxalate, succinate, benzoate and hydrochloride salts.
5. The benzoate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine.
6. A pharmaceutical composition comprising N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethylamine or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or excipient.
7. A pharmaceutical composition as claimed in claim 6, wherein the pharmaceutically acceptable salt is selected from the group consisting of the oxalate, succinate, benzoate and hydrochloride salts.
8. A pharmaceutical composition comprising the benzoate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine in association with a pharmaceutically acceptable carrier or excipient.
9. An anti-migraine pharmaceutical composition comprising an acceptable, anti-migraine effective amount of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
10. A composition according to claim 9, comprising said N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine.
11. A composition according to claim 9, comprising the benzoate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine.
12. Use of N,N-dimethyl-2-[5-(1,2,4-triazol-1-yl-methyl)-1H-indol-3-yl]ethylamine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of migraine and associated conditions.
13. Use of a pharmaceutically acceptable salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, in the manufacture of a medicament for the treatment of migraine and associated conditions, said salt being selected from the group consisting of the oxalate, succinate, benzoate and hydrochloride salts.
14. Use of the benzoate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine for the manufacture of a medicament for the treatment of migraine and associated conditions.
15. N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, or a pharmaceutically acceptable salt thereof, for use in the treatment of migraine or associated conditions.
16. N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, for use in the treatment of migraine or associated conditions.
17. A pharmaceutically acceptable salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethylamine, for use in the treatment of migraine or associated conditions, said salt being selected from the group consisting of the oxalate, succinate, benzoate and hydrochloride salts.
18. The benzoate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, for use in the treatment of migraine or associated conditions.
19. Use of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, or a pharmaceutically acceptable salt thereof as a 5-HT1-like receptor agonist.
20. Use of a pharmaceutically acceptable salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, as a 5-HT1-like receptor agonist.
21. Use of the benzoate salt of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine, as a 5-HT1-like receptor agonist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002238140A CA2238140C (en) | 1991-02-01 | 1992-01-28 | Imidazole, triazole and tetrazole derivatives |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9102222.8 | 1991-02-01 | ||
GB919102222A GB9102222D0 (en) | 1991-02-01 | 1991-02-01 | Therapeutic agents |
GB9106917.9 | 1991-04-03 | ||
GB919106917A GB9106917D0 (en) | 1991-04-03 | 1991-04-03 | Therapeutic agents |
GB9113415.5 | 1991-06-21 | ||
GB919113415A GB9113415D0 (en) | 1991-06-21 | 1991-06-21 | Therapeutic agents |
GB9122451.9 | 1991-10-23 | ||
GB919122451A GB9122451D0 (en) | 1991-10-23 | 1991-10-23 | Therapeutic agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002238140A Division CA2238140C (en) | 1991-02-01 | 1992-01-28 | Imidazole, triazole and tetrazole derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2060139A1 CA2060139A1 (en) | 1992-08-02 |
CA2060139C true CA2060139C (en) | 1998-12-01 |
Family
ID=27450619
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002060139A Expired - Lifetime CA2060139C (en) | 1991-02-01 | 1992-01-28 | Triazole derivative |
CA002238140A Expired - Lifetime CA2238140C (en) | 1991-02-01 | 1992-01-28 | Imidazole, triazole and tetrazole derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002238140A Expired - Lifetime CA2238140C (en) | 1991-02-01 | 1992-01-28 | Imidazole, triazole and tetrazole derivatives |
Country Status (30)
Country | Link |
---|---|
US (4) | US5298520A (en) |
EP (2) | EP0778275B1 (en) |
JP (1) | JP2500280B2 (en) |
KR (1) | KR100212111B1 (en) |
CN (4) | CN1038681C (en) |
AT (1) | ATE158582T1 (en) |
BG (1) | BG62024B2 (en) |
CA (2) | CA2060139C (en) |
CY (1) | CY2095B1 (en) |
CZ (1) | CZ283018B6 (en) |
DE (2) | DE69222329T2 (en) |
DK (1) | DK0497512T3 (en) |
ES (2) | ES2106822T3 (en) |
FI (1) | FI107154B (en) |
GR (2) | GR3025026T3 (en) |
HR (1) | HRP930777B1 (en) |
HU (2) | HU222350B1 (en) |
IE (1) | IE920342A1 (en) |
IL (1) | IL100756A (en) |
LU (1) | LU90338I2 (en) |
LV (1) | LV12090B (en) |
MX (1) | MX9200405A (en) |
NL (1) | NL980019I1 (en) |
NO (2) | NO180447C (en) |
NZ (1) | NZ241394A (en) |
SA (1) | SA94140534B1 (en) |
SG (1) | SG50409A1 (en) |
SI (1) | SI9210101B (en) |
SK (1) | SK278998B6 (en) |
YU (1) | YU48236B (en) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ238424A (en) * | 1990-06-07 | 1993-12-23 | Wellcome Found | 3,5-substituted indole derivatives; medicaments and preparatory processes. |
US5607951A (en) * | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
US5559246A (en) * | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
US5559129A (en) * | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
US5492919A (en) * | 1991-08-03 | 1996-02-20 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
GB9201038D0 (en) * | 1992-01-16 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
TW288010B (en) * | 1992-03-05 | 1996-10-11 | Pfizer | |
ATE205202T1 (en) * | 1992-03-13 | 2001-09-15 | Merck Sharp & Dohme | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES |
GB9207396D0 (en) * | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
US6380233B1 (en) | 1992-04-07 | 2002-04-30 | Pfizer Inc | Indole derivatives as 5-HT1 agonists |
BR9306201A (en) | 1992-04-07 | 1998-06-23 | Pfizer | Indole derivatives as 5-ht1 agonists |
AU670270B2 (en) * | 1992-04-10 | 1996-07-11 | Pfizer Inc. | Acylaminoindole derivatives as 5-HT1 agonists |
GB9207930D0 (en) * | 1992-04-10 | 1992-05-27 | Pfizer Ltd | Indoles |
GB9208463D0 (en) * | 1992-04-16 | 1992-06-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
GB9211277D0 (en) | 1992-05-28 | 1992-07-15 | Glaxo Group Inc | Pharmaceutical compositions |
CZ282060B6 (en) * | 1992-06-05 | 1997-05-14 | Merck Sharp And Dohme Limited | Sulfate salt of substituted triazole, process of its preparation, and pharmaceutical preparation containing thereof |
GB9215526D0 (en) * | 1992-07-22 | 1992-09-02 | Merck Sharp & Dohme | Chemical process |
JPH07509452A (en) * | 1992-07-24 | 1995-10-19 | メルク シヤープ エンド ドーム リミテツド | Imidazole, triazole and tetrazole derivatives |
IL106445A (en) * | 1992-07-30 | 1998-01-04 | Merck Sharp & Dohme | 4-substituted 1, 2, 4-triazole derivatives, their preparation and pharmaceutical compositions containing them |
TW251284B (en) * | 1992-11-02 | 1995-07-11 | Pfizer | |
GB9226537D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
FR2701026B1 (en) * | 1993-02-02 | 1995-03-31 | Adir | New derivatives of indole, indazole and benzisoxazole, process for their preparation and pharmaceutical compositions containing them. |
US6060473A (en) * | 1993-04-01 | 2000-05-09 | Ucb S.A. - Dtb | 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands |
US5817679A (en) * | 1993-04-01 | 1998-10-06 | University Of Virginia | 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands |
CN1129933A (en) * | 1993-08-31 | 1996-08-28 | 辉瑞大药厂 | 5-arylindole derivatives |
US6077846A (en) * | 1993-09-10 | 2000-06-20 | Ucb, S.A. | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
GB9402016D0 (en) * | 1994-02-02 | 1994-03-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9402011D0 (en) * | 1994-02-02 | 1994-03-30 | Merck Sharp & Dohme | Therapeutic agents |
US6117889A (en) * | 1994-04-01 | 2000-09-12 | University Of Virginia | 7-Azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents |
JPH10501212A (en) * | 1994-05-19 | 1998-02-03 | メルク シヤープ エンド ドーム リミテツド | Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-HT <1D> -alpha agonists |
US5552402A (en) * | 1994-05-19 | 1996-09-03 | Merck, Sharp & Dohme Ltd. | Five-membered heteroaromatic compounds as 5-HT receptor agonists |
GB9410031D0 (en) * | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
US5567824A (en) * | 1994-05-24 | 1996-10-22 | Merck & Co., Inc. | Palladium catalyzed ring closure of triazolyltryptamine |
CA2194984C (en) * | 1994-07-26 | 2002-07-02 | John Eugene Macor | 4-indole derivatives as serotonin agonists and antagonists |
WO1996004274A1 (en) * | 1994-08-02 | 1996-02-15 | Merck Sharp & Dohme Limited | Azetidine, pyrrolidine and piperidine derivatives |
GB9417310D0 (en) | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
GB9501865D0 (en) * | 1995-01-31 | 1995-03-22 | Merck Sharp & Dohme | Therapeutic agents |
US5484763A (en) * | 1995-02-10 | 1996-01-16 | American Cyanamid Company | Substituted benzisoxazole and benzisothiazole herbicidal agents |
CA2215322A1 (en) * | 1995-03-20 | 1996-09-26 | Stephen Warren Kaldor | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
US6245768B1 (en) | 1995-06-05 | 2001-06-12 | Neurogen Corporation | 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
US5656632A (en) * | 1995-06-05 | 1997-08-12 | Neurogen Corporation | 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands |
US5602168A (en) * | 1995-07-10 | 1997-02-11 | Neurogen Corporation | 1-(N'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specific ligands |
ZA965837B (en) * | 1995-07-11 | 1997-01-31 | Merck & Co Inc | A triazolylmethyl-indole ethylamine bisulfate salt |
EP0840733B1 (en) * | 1995-07-11 | 2001-10-24 | Merck & Co., Inc. | A triazolylmethyl-indole ethylamine bisulfate salt |
US5942536A (en) * | 1995-10-10 | 1999-08-24 | Eli Lilly And Company | N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists |
US5998415A (en) * | 1995-11-02 | 1999-12-07 | Merck Sharp & Dohme Ltd. | Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors |
GB9523583D0 (en) * | 1995-11-17 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
GB9610978D0 (en) * | 1996-05-24 | 1996-07-31 | Merck Sharp & Dohme | Therapeutic agents |
US5877329A (en) * | 1996-08-13 | 1999-03-02 | Merck & Co., Inc. | Palladium catalyzed indolization |
US5811551A (en) * | 1996-08-13 | 1998-09-22 | Merck & Co., Inc. | Palladium catalyzed indolization |
US5808064A (en) * | 1996-08-13 | 1998-09-15 | Merck & Co., Inc. | Palladium catalyzed indolization |
JP2001503668A (en) | 1996-08-19 | 2001-03-21 | フォルクスワーゲン・アクチェンゲゼルシャフト | NO ▲ lower x ▼ absorber |
EP1342496B1 (en) | 1996-08-19 | 2007-05-23 | Volkswagen AG | Spark-ignited internal combustion engine with an NOx-adsorber |
GB9620777D0 (en) * | 1996-10-07 | 1996-11-20 | Merck Sharp & Dohme | Therapeutic use |
US5998438A (en) * | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
US6602889B1 (en) | 1998-03-09 | 2003-08-05 | H. Lundbeck A.S. | 5-heteroaryl substituted indoles |
JP2002528498A (en) * | 1998-11-02 | 2002-09-03 | メルク エンド カムパニー インコーポレーテッド | Migraine treatment method and pharmaceutical composition |
US5994352A (en) * | 1998-11-13 | 1999-11-30 | Pfizer Inc. | 5-arylindole derivatives |
CO5190664A1 (en) * | 1999-06-30 | 2002-08-29 | Pfizer Prod Inc | COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA ADMINISTRATION OF A 5HT RECEPTOR, CAFFEINE AND A CYCLLOXYGENASA-2 INHIBITOR |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6864262B2 (en) * | 2000-11-29 | 2005-03-08 | Eli Lilly And Company | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof |
US20030096379A1 (en) * | 2001-03-28 | 2003-05-22 | Kilgore James L. | Method for producing tryptamine derivatives |
DE10214228A1 (en) * | 2002-03-22 | 2003-10-02 | Bdd Group Holding Ag Zug | Deuterated substituted indoles and medicinal products containing these compounds |
ES2297216T3 (en) | 2002-06-21 | 2008-05-01 | Suven Life Sciences Limited | ARILSULFONIL TETRACICLIC INDOLES THAT HAVE AFFINITY WITH THE SEROTONINE RECEIVER. |
CA2490115C (en) | 2002-06-21 | 2009-09-01 | Suven Life Sciences Limited | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
ES2204303B2 (en) * | 2002-08-07 | 2004-12-16 | Laboratorios Vita, S.A. | PROCEDURE FOR OBTAINING A PHARMACEUTICALLY ACTIVE COMPOUND. |
ATE401307T1 (en) | 2002-11-28 | 2008-08-15 | Suven Life Sciences Ltd | N-ARYLSULFONYL-2-SUBSTITUTED INDOLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
CN1720227A (en) | 2002-11-28 | 2006-01-11 | 苏文生命科学有限公司 | N-arylsulfonyl-3-aminoalkoxyindoles |
DK1581538T3 (en) | 2002-12-18 | 2007-06-25 | Suven Life Sciences Ltd | Tetracyclic 3-substituted indoles with serotonin receptor affinity |
EP2666772B1 (en) * | 2002-12-20 | 2017-03-01 | Basf Se | Synthesis of amines and intermediates for the synthesis thereof |
KR100572325B1 (en) * | 2003-12-17 | 2006-04-19 | 삼성전자주식회사 | Ion Implantation Apparatus and Ion Implantation Method Using the Same |
WO2005068453A2 (en) * | 2004-01-09 | 2005-07-28 | Ratiopharm Gmbh | Crystalline forms of rizatriptan benzoate |
US7786156B2 (en) | 2004-01-28 | 2010-08-31 | Ratiopharm Gmbh | Synthesis methods and intermediates for the manufacture of Rizatriptan |
WO2006053116A2 (en) * | 2004-11-10 | 2006-05-18 | Dr. Reddy's Laboratories Ltd. | Rizatriptan process |
CN101072759B (en) | 2004-11-18 | 2013-06-19 | Synta医药公司 | Triazole compounds that modulate HSP90 activity |
WO2006082598A2 (en) * | 2005-02-01 | 2006-08-10 | Natco Pharma Limited | Novel crystalline forms of rizatriptan benzoate |
WO2006137083A1 (en) * | 2005-06-20 | 2006-12-28 | Natco Pharma Limited | Improved process for the preparation of rizatriptan benzoate |
ES2270717B1 (en) * | 2005-08-08 | 2008-03-01 | Ragactives, S.L. | PROCEDURE FOR OBTAINING TRIPTAMINE DERIVATIVES. |
EP1915369A4 (en) * | 2005-08-11 | 2010-09-08 | Merck Frosst Canada Ltd | Novel substituted 1,2,3-t ii azolylmethyl-benzothiophene or -indole and their use as leukotiiene biosynthesis inhibitors |
JP5118039B2 (en) * | 2005-08-18 | 2013-01-16 | シンタ ファーマシューティカルズ コーポレーション | Triazole compounds that modulate HSP90 activity |
WO2007054979A1 (en) * | 2005-11-14 | 2007-05-18 | Matrix Laboratories Ltd | Process for the large scale production of rizatriptan benzoate |
US20110313171A1 (en) | 2006-01-19 | 2011-12-22 | Chandra Purna Ray | Conversion of aromatic diazonium salt to aryl hydrazine |
EP2032545A2 (en) * | 2006-05-25 | 2009-03-11 | Synta Pharmaceuticals Corporation | Compounds that modulate hsp90 activity and methods for identifying same |
US8318790B2 (en) * | 2006-05-25 | 2012-11-27 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
AU2007267859B2 (en) | 2006-05-25 | 2012-04-12 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
JP5410965B2 (en) * | 2006-05-25 | 2014-02-05 | シンタ ファーマシューティカルズ コーポレーション | Triazole compounds that modulate Hsp90 activity |
US8653066B2 (en) | 2006-10-09 | 2014-02-18 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
AU2008259518A1 (en) * | 2007-06-04 | 2008-12-11 | Generics [Uk] Limited | Novel process |
AU2008310883A1 (en) * | 2007-10-09 | 2009-04-16 | Hamann, Mark T | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
US20090294028A1 (en) * | 2008-06-03 | 2009-12-03 | Nanochip, Inc. | Process for fabricating high density storage device with high-temperature media |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
WO2011041635A2 (en) * | 2009-10-02 | 2011-04-07 | Cardiofocus, Inc. | Cardiac ablation system with inflatable member having multiple inflation settings |
WO2011097602A1 (en) * | 2010-02-08 | 2011-08-11 | Biomarin Pharmaceutical Inc. | Processes of synthesizing dihydropyridophthalazinone derivatives |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
WO2013120045A1 (en) * | 2012-02-10 | 2013-08-15 | University Of Utah Research Foundation | Substituted 1h-indazol-1-ol analogs as inhibitors of beta catenin/tcf protein-protein interactions |
CN103739594A (en) * | 2012-10-17 | 2014-04-23 | 南京大学 | Schiff base derivatives containing pyrazine ring and triazole structure and preparation method of the derivatives |
DK3300500T3 (en) | 2015-05-20 | 2020-05-18 | Amgen Inc | TRIAZOLAGONISTS OF THE APJ RECEPTOR |
CN108430581A (en) * | 2015-10-28 | 2018-08-21 | 雷迪博士实验室有限公司 | pharmaceutical composition for Rizatriptan |
US20210069122A1 (en) | 2016-01-27 | 2021-03-11 | Instar Technologies A.S. | Oromucosal nanofiber carriers for therapeutic treatment |
JP2019507181A (en) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | Pharmaceutical composition |
GB2570382B (en) | 2016-04-27 | 2020-07-29 | Univ Puerto Rico | 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases |
WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
WO2018097945A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Heteroaryl-substituted triazoles as apj receptor agonists |
EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
EP3704122B1 (en) | 2017-11-03 | 2021-09-01 | Amgen Inc. | Fused triazole agonists of the apj receptor |
WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3475437A (en) * | 1964-06-05 | 1969-10-28 | Boehringer Sohn Ingelheim | 3-tertiary amino lower alkylpseudoindoles |
GB1237008A (en) * | 1968-12-18 | 1971-06-30 | Pfizer Ltd | Novel indoline derivatives |
US3686213A (en) * | 1970-08-28 | 1972-08-22 | American Cyanamid Co | Substituted aminoethyl indoles |
DE2520816C3 (en) * | 1975-05-09 | 1979-02-15 | Bayer Ag, 5090 Leverkusen | Methine dyes |
ZA795239B (en) * | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
ZA815541B (en) * | 1980-08-12 | 1983-03-30 | Glaxo Group Ltd | Heterocyclic compounds |
ES8300699A1 (en) * | 1980-08-12 | 1982-11-01 | Glaxo Group Ltd | Heterocyclic compounds |
IT1171449B (en) * | 1980-08-12 | 1987-06-10 | Glaxo Group Ltd | INDOLIC HETEROCYCLIC COMPOUNDS PROCEDURE FOR THE PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
ZW19381A1 (en) * | 1980-08-12 | 1983-03-09 | Glaxo Group Ltd | Heterocyclic compounds |
US4453001A (en) * | 1982-02-22 | 1984-06-05 | Sandoz, Inc. | Isoxazolyl indolamines as intermediates |
JPS58150576A (en) * | 1982-03-03 | 1983-09-07 | Sumitomo Chem Co Ltd | Novel 1,2,4-oxadiazole derivative |
US4692531A (en) * | 1984-06-22 | 1987-09-08 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
GB8419575D0 (en) * | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
DE3430284A1 (en) * | 1984-08-17 | 1986-02-27 | Troponwerke GmbH & Co KG, 5000 Köln | NEW TRYPTAMINE DERIVATIVES, A METHOD FOR THEIR PRODUCTION AND THEIR USE |
US4663526A (en) * | 1984-12-26 | 1987-05-05 | Emil Kamieniecki | Nondestructive readout of a latent electrostatic image formed on an insulating material |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
DE3531658A1 (en) * | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | HETEROCYCLICALLY SUBSTITUTED INDOLE, INTERMEDIATE PRODUCTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS |
DE3678805D1 (en) * | 1985-11-08 | 1991-05-23 | Glaxo Group Ltd | INDOLDER DERIVATIVES. |
GB8527619D0 (en) * | 1985-11-08 | 1985-12-11 | Glaxo Group Ltd | Chemical compounds |
US4881967A (en) * | 1986-12-10 | 1989-11-21 | E. I. Du Pont De Nemours And Company | Heterocyclic 2,3-dihydrobenzofuran herbicides |
US5225431A (en) * | 1987-10-23 | 1993-07-06 | Burroughs Wellcome Co. | Therapeutic substituted indole compounds and compositions thereof |
GB8724912D0 (en) * | 1987-10-23 | 1987-11-25 | Wellcome Found | Indole derivatives |
NZ227841A (en) * | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
NZ238424A (en) * | 1990-06-07 | 1993-12-23 | Wellcome Found | 3,5-substituted indole derivatives; medicaments and preparatory processes. |
US5492919A (en) * | 1991-08-03 | 1996-02-20 | Smithkline Beecham P.L.C. | 5-HT4 receptor antagonists |
KR930011238A (en) * | 1991-11-12 | 1993-06-24 | 오리 노리오 | Memory cell of static RAM and memory cell array |
US5436246A (en) * | 1992-09-17 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | Serotonin receptor agents |
-
1992
- 1992-01-23 SK SK198-92A patent/SK278998B6/en not_active IP Right Cessation
- 1992-01-23 CZ CS92198A patent/CZ283018B6/en not_active IP Right Cessation
- 1992-01-24 DK DK92300617.5T patent/DK0497512T3/en active
- 1992-01-24 DE DE69222329T patent/DE69222329T2/en not_active Expired - Lifetime
- 1992-01-24 EP EP97200467A patent/EP0778275B1/en not_active Expired - Lifetime
- 1992-01-24 DE DE1999175007 patent/DE19975007I2/en active Active
- 1992-01-24 ES ES92300617T patent/ES2106822T3/en not_active Expired - Lifetime
- 1992-01-24 AT AT92300617T patent/ATE158582T1/en active
- 1992-01-24 NZ NZ241394A patent/NZ241394A/en not_active IP Right Cessation
- 1992-01-24 ES ES97200467T patent/ES2162188T3/en not_active Expired - Lifetime
- 1992-01-24 IL IL10075692A patent/IL100756A/en not_active IP Right Cessation
- 1992-01-24 SG SG1996000418A patent/SG50409A1/en unknown
- 1992-01-24 EP EP92300617A patent/EP0497512B1/en not_active Expired - Lifetime
- 1992-01-28 US US07/827,187 patent/US5298520A/en not_active Expired - Lifetime
- 1992-01-28 CA CA002060139A patent/CA2060139C/en not_active Expired - Lifetime
- 1992-01-28 CA CA002238140A patent/CA2238140C/en not_active Expired - Lifetime
- 1992-01-30 YU YU10192A patent/YU48236B/en unknown
- 1992-01-30 SI SI9210101A patent/SI9210101B/en unknown
- 1992-01-30 MX MX9200405A patent/MX9200405A/en unknown
- 1992-01-31 JP JP4059849A patent/JP2500280B2/en not_active Expired - Lifetime
- 1992-01-31 HU HU9200299A patent/HU222350B1/en active IP Right Grant
- 1992-01-31 IE IE034292A patent/IE920342A1/en active Protection Beyond IP Right Term
- 1992-01-31 FI FI920442A patent/FI107154B/en active Protection Beyond IP Right Term
- 1992-01-31 NO NO920424A patent/NO180447C/en not_active IP Right Cessation
- 1992-02-01 KR KR1019920001592A patent/KR100212111B1/en not_active IP Right Cessation
- 1992-02-01 CN CN92101189A patent/CN1038681C/en not_active Expired - Lifetime
-
1993
- 1993-04-02 HR HR930777A patent/HRP930777B1/en not_active IP Right Cessation
- 1993-07-14 BG BG97943A patent/BG62024B2/en unknown
- 1993-11-22 US US08/156,140 patent/US5451588A/en not_active Expired - Lifetime
-
1994
- 1994-01-30 SA SA94140534A patent/SA94140534B1/en unknown
-
1995
- 1995-05-10 US US08/438,621 patent/US5602162A/en not_active Expired - Lifetime
- 1995-05-25 US US08/452,185 patent/US5602163A/en not_active Expired - Lifetime
- 1995-06-28 HU HU95P/P00500P patent/HU211516A9/en unknown
-
1996
- 1996-11-25 CN CN96121797A patent/CN1128617C/en not_active Expired - Lifetime
- 1996-11-25 CN CN96121796A patent/CN1060479C/en not_active Expired - Lifetime
- 1996-11-25 CN CN96117268A patent/CN1061654C/en not_active Expired - Lifetime
-
1997
- 1997-10-15 GR GR970402671T patent/GR3025026T3/en unknown
-
1998
- 1998-03-17 LV LVP-98-54A patent/LV12090B/en unknown
- 1998-06-08 NL NL980019C patent/NL980019I1/en unknown
- 1998-07-17 CY CY9800017A patent/CY2095B1/en unknown
-
1999
- 1999-01-13 LU LU90338C patent/LU90338I2/en unknown
- 1999-04-09 NO NO1999005C patent/NO1999005I1/en unknown
-
2001
- 2001-10-11 GR GR20010401586T patent/GR3036864T3/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2060139C (en) | Triazole derivative | |
JP3309982B2 (en) | Imidazole, triazole and tetrazole derivatives | |
EP0640085B1 (en) | Fused imidazole and triazole derivatives as 5-ht1 receptor agonists | |
IE63174B1 (en) | New anellated indole derivatives | |
AU664102B2 (en) | 4-substituted 1,2,4-triazole derivatives | |
FR2722190A1 (en) | 1-BENZYL-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
NO179612B (en) | Analogous Process for Preparation of 3-arylcarbonyl-1-aminoalkyl-1H-indole Compounds | |
GB2315673A (en) | Treatment of migraine | |
CA2379572C (en) | Polymorphic salt | |
KR20010080594A (en) | Eletriptan Hydrobromide Monohydrate | |
US5607957A (en) | Imidazole, triazole and tetrazole derivatives | |
CZ85592A3 (en) | 6-heterocyclic 4-amino-1,2,2a,3,4,5-tetrahydrobenzo(cd)indole, process of its preparation and a pharmaceutical preparation in which it is contained | |
HU203345B (en) | Process for producing ergoline derivatives and pharmaceutical compositions comprising same | |
JPH02300184A (en) | Indole derivative | |
US5389684A (en) | Naphthalene carboxamides | |
US5770611A (en) | Indole derivatives as 5HT1 -like agonists | |
US5902819A (en) | Triazole derivatives | |
JP2003514811A (en) | Novel amidine derivatives, their preparation and their use as medicaments | |
WO1995021167A1 (en) | Triazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |